| Status | Available to order |
| EMMA ID | EM:02611 |
| International strain name | CnbcLmon:NMRI-Tg(tetO-Tyr)1335Lmon Tg(Tyr-rtTA)4111Lmon |
| Alternative name | TRETyBS/HSTyrTET |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Tyr-rtTA)4111Lmon, Tg(tetO-Tyr)1335Lmon, Tyrc |
| Gene/Transgene symbol | Tg(Tyr-rtTA)4111Lmon, Tg(tetO-Tyr)1335Lmon, Tyr |
| Provider | Lluis Montoliu |
| Provider affiliation | Departamento de Biologia Molecular y Celular, CNB-CSIC, Centro Nacional de Biotecnologia |
| Genetic information | Double transgenic mice carrying two constructs for doxycycline-mediated tyrosinase gene regulation (TET-ON model). Animal mouse model of oculocutaneous albinism type 1 (OCA1). It uses the first Tet system developed by H. Bujard and colleagues, therefore the version used of the transactivator was "Tet On/Off" (Tet On scheme, using rtTA) and the version of the Tet promoter was "PTRE". See PubMed ID:15250938. |
| Phenotypic information | In the off status, externally undistinguishable from a common albino phenotype. Upon doxycycline/tetracycline treatment from first gestational week pups will show a darker ruby eye colour. Coat colour is not modified by doxycycline/tetracycline treatment. |
| Breeding history | Transgenic mice were initially generated in FVB/HanHsd albino inbred mice but expanded in HsdWin:NMRI albino outbred mice to avoid the retinal degeneration mutation (Pdebrd1), carried by the FVB/HanHsd genotype. Mice were bred to double transgenic homozygosity and have been maintained since then as double transgenic homozygous in HsdWin:NMRI albino outbred mice (more than 20 generations). |
| References |
|
| Homozygous fertile | yes |
| Homozygous viable | yes |
| Homozygous matings required | yes |
| Immunocompromised | no |
| Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
| Animals used for archiving | homozygous NMRI, wild-type NMRI |
| Stage of embryos | 8-cell |
Orphanet associated rare diseases, based on orthologous gene matching
